SI0760649T1 - Fluticasone propionate formulations - Google Patents

Fluticasone propionate formulations

Info

Publication number
SI0760649T1
SI0760649T1 SI9530550T SI9530550T SI0760649T1 SI 0760649 T1 SI0760649 T1 SI 0760649T1 SI 9530550 T SI9530550 T SI 9530550T SI 9530550 T SI9530550 T SI 9530550T SI 0760649 T1 SI0760649 T1 SI 0760649T1
Authority
SI
Slovenia
Prior art keywords
pct
fluticasone propionate
formulation
sec
date
Prior art date
Application number
SI9530550T
Other languages
English (en)
Slovenian (sl)
Inventor
David Alexander Glaxo Research and TAINSH
Trevor Leslie Glaxo Research and ILOTT
Dorothy Jill Snell
Li Fong Lam
Original Assignee
Glaxo Wellcome Australia Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Australia Ltd. filed Critical Glaxo Wellcome Australia Ltd.
Publication of SI0760649T1 publication Critical patent/SI0760649T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
SI9530550T 1994-05-21 1995-05-19 Fluticasone propionate formulations SI0760649T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9410222A GB9410222D0 (en) 1994-05-21 1994-05-21 Medicaments
EP95920841A EP0760649B1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations
PCT/EP1995/001913 WO1995031964A1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations

Publications (1)

Publication Number Publication Date
SI0760649T1 true SI0760649T1 (en) 2002-04-30

Family

ID=10755515

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530550T SI0760649T1 (en) 1994-05-21 1995-05-19 Fluticasone propionate formulations

Country Status (29)

Country Link
US (1) US5993781A (fi)
EP (1) EP0760649B1 (fi)
JP (1) JPH10500420A (fi)
KR (2) KR100361413B1 (fi)
CN (1) CN1098680C (fi)
AT (1) ATE207734T1 (fi)
AU (1) AU710821B2 (fi)
BR (1) BR9507746A (fi)
CA (1) CA2190763A1 (fi)
CY (1) CY2294B1 (fi)
CZ (1) CZ285966B6 (fi)
DE (1) DE69523587T2 (fi)
DK (1) DK0760649T3 (fi)
ES (1) ES2164767T3 (fi)
FI (1) FI118512B (fi)
GB (1) GB9410222D0 (fi)
HK (1) HK1004192A1 (fi)
HU (1) HU223316B1 (fi)
IL (1) IL113794A (fi)
MX (1) MX9605650A (fi)
NO (1) NO313785B1 (fi)
NZ (1) NZ287425A (fi)
PL (1) PL180318B1 (fi)
PT (1) PT760649E (fi)
RU (1) RU2161485C2 (fi)
SI (1) SI0760649T1 (fi)
TW (1) TW438604B (fi)
WO (1) WO1995031964A1 (fi)
ZA (1) ZA954101B (fi)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
GB9610341D0 (en) * 1996-05-17 1996-07-24 Andaris Ltd Formulation for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
DE60325459D1 (de) 2002-02-19 2009-02-05 Resolution Chemicals Ltd Auf lösungsmitteln basierende sterilisation von steroiden
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004032980A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
GB0425266D0 (en) * 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
MX361886B (es) 2012-05-08 2018-12-18 Nicox Ophthalmics Inc Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos.
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007770A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising corticosteroid and sorbitol
WO2014007772A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
WO2014007781A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions
DE102012111077A1 (de) * 2012-11-16 2014-05-22 Justus-Liebig-Universität Giessen Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
KR102379309B1 (ko) * 2014-09-15 2022-03-28 베로나 파마 피엘씨 Ｒｐｌ５５４를 포함하는 액상 흡입제
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
JP3280974B2 (ja) * 1991-12-12 2002-05-13 グラクソ、グループ、リミテッド 医 薬
AU673660C (en) * 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
GB9419536D0 (en) * 1994-09-28 1994-11-16 Glaxo Inc Medicaments

Also Published As

Publication number Publication date
CY2294B1 (en) 2003-07-04
EP0760649A1 (en) 1997-03-12
PL317225A1 (en) 1997-03-17
US5993781A (en) 1999-11-30
NO313785B1 (no) 2002-12-02
AU2614595A (en) 1995-12-18
ATE207734T1 (de) 2001-11-15
CA2190763A1 (en) 1995-11-30
PL180318B1 (pl) 2001-01-31
CN1148804A (zh) 1997-04-30
HU223316B1 (hu) 2004-05-28
NZ287425A (en) 1998-05-27
BR9507746A (pt) 1997-08-19
ZA954101B (en) 1996-01-29
JPH10500420A (ja) 1998-01-13
NO964938L (no) 1996-11-20
FI964634A0 (fi) 1996-11-20
HK1004192A1 (en) 1998-11-20
KR100361413B1 (ko) 2003-02-19
TW438604B (en) 2001-06-07
HU9603227D0 (en) 1997-01-28
KR970703132A (ko) 1997-07-03
PT760649E (pt) 2002-04-29
CN1098680C (zh) 2003-01-15
MX9605650A (es) 1998-05-31
DE69523587D1 (de) 2001-12-06
DK0760649T3 (da) 2002-01-28
CZ342396A3 (en) 1997-07-16
DE69523587T2 (de) 2002-06-27
EP0760649B1 (en) 2001-10-31
RU2161485C2 (ru) 2001-01-10
KR970703130A (ko) 1997-07-03
WO1995031964A1 (en) 1995-11-30
FI964634A (fi) 1996-11-20
FI118512B (fi) 2007-12-14
GB9410222D0 (en) 1994-07-06
AU710821B2 (en) 1999-09-30
NO964938D0 (no) 1996-11-20
HUT76552A (en) 1997-09-29
IL113794A0 (en) 1995-08-31
CZ285966B6 (cs) 1999-12-15
IL113794A (en) 2000-10-31
ES2164767T3 (es) 2002-03-01

Similar Documents

Publication Publication Date Title
HK1004192A1 (en) Fluticasone propionate formulations
GR3034477T3 (en) Pharmaceutical aerosol containing at least one sugar
CA2125665A1 (en) Medicaments
GB9606677D0 (en) Process and device
HK185596A (en) Non-chlorofluoro-carbon aerosol formulations
MY108748A (en) Medicaments
PL319833A1 (en) Compounds and composition for carrying active media
CA2310222A1 (en) New composition of matter
AU3038197A (en) Aerosol formulations
IL115920A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING omega-SUBSTITUTED 2,2-DICHLOROALKANECARBOXYLIC ACIDS, SOME SUCH NEW COMPOUNDS AND PROCESS FOR THEIR PREPARATION
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
BR9508021A (pt) Composição farmacêutica para o tratamento de distúrbios esquizofrênicos, uso de um agente imunossupressor, e, processo de tratamento de um paciente esquizofrênico
CZ38396A3 (en) Aerosol formulation for administration in the form of a spray, container for aerosol and its use
IL110289A0 (en) Pharmaceutical compositions comprising 4'-iodo-4'- deoxydoxorubicin for treating amyloidosis
AU665397B2 (en) Fungicidal compositions
IL113544A0 (en) Active peptide and its preparation
IL117734A (en) Anellated beta-carbolines their preparation and pharmaceutical compositions containing them